Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BeyondSpring Inc.    BYSI   KYG108301006

BEYONDSPRING INC.

(BYSI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
BEYONDSPRING INC.-10.19%419
-
GILEAD SCIENCES, INC.-7.34%75 487
REGENERON PHARMACEUTICALS52.44%60 234
VERTEX PHARMACEUTICALS-3.46%55 058
WUXI APPTEC CO., LTD.64.60%39 515
BEIGENE, LTD.82.54%27 421
GENMAB A/S50.39%23 222
BIONTECH SE158.91%20 893
HUALAN BIOLOGICAL ENGINEERI..110.85%15 640
ARGENX SE53.06%12 350
MYOKARDIA, INC.205.14%11 859
-
SAREPTA THERAPEUTICS, INC.6.37%10 776
NEUROCRINE BIOSCIENCES, INC..-10.86%8 936
ASCENDIS PHARMA A/S12.16%8 302
MIRATI THERAPEUTICS, INC.43.52%8 237
BIOCON LIMITED49.68%7 073
More Results
Financials (USD)
Sales 2020 - - -
Net income 2020 -60,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -6,69x
Yield 2020 -
Capitalization 419 M 419 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 29,0x
Nbr of Employees 61
Free-Float 12,0%
Upcoming event on BEYONDSPRING INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes